Intersect ENT Inc (NASDAQ:XENT) has been assigned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $33.43.

A number of research analysts recently weighed in on the company. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a research note on Saturday, December 30th. Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Northland Securities reaffirmed a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $41.00 target price on shares of Intersect ENT in a report on Friday, December 15th.

In other news, CFO Jeryl L. Hilleman sold 12,835 shares of Intersect ENT stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $33.81, for a total transaction of $433,951.35. Following the sale, the chief financial officer now owns 25,767 shares of the company’s stock, valued at approximately $871,182.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lisa D. Earnhardt sold 10,685 shares of Intersect ENT stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.87, for a total value of $340,530.95. Following the sale, the insider now directly owns 487,868 shares in the company, valued at approximately $15,548,353.16. The disclosure for this sale can be found here. Insiders sold a total of 106,886 shares of company stock worth $3,320,094 in the last ninety days. Insiders own 13.70% of the company’s stock.

Several large investors have recently made changes to their positions in XENT. Great West Life Assurance Co. Can acquired a new stake in shares of Intersect ENT during the 3rd quarter worth approximately $116,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Intersect ENT during the 3rd quarter worth approximately $117,000. Legal & General Group Plc grew its holdings in shares of Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares in the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Intersect ENT during the 2nd quarter worth approximately $205,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Intersect ENT during the 3rd quarter worth approximately $228,000. 86.31% of the stock is currently owned by institutional investors.

Intersect ENT (XENT) opened at $34.35 on Monday. Intersect ENT has a one year low of $11.75 and a one year high of $35.34. The firm has a market capitalization of $1,011.81, a P/E ratio of -54.52 and a beta of 0.67.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business had revenue of $22.31 million for the quarter, compared to the consensus estimate of $21.53 million. During the same period last year, the business earned ($0.22) EPS. The firm’s revenue was up 20.8% compared to the same quarter last year. equities analysts anticipate that Intersect ENT will post -0.63 EPS for the current year.

WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/intersect-ent-inc-xent-receives-consensus-rating-of-buy-from-analysts.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.